Dolan Matthew Vincent's Form 4 filing
Dexcom Inc (DXCM) · filed Jan 30, 2025
- Accession no.
- 0001093557-25-000018
- Filed
- Jan 30, 2025
- Trade date
- Jan 28-29, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $102.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dolan Matthew VincentCIK 0001914994 | Officer (EVP, Strategy & Corporate Dev) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 28, 2025 | Common Stock | AGrant or awardAcquired | +3,048 | $0.00 | $0 | 43,227 | Direct | |
| Jan 29, 2025 | Common Stock | SSaleDisposed | −1,183 | $86.91 | −$102,814.53 | 42,044 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.